

Intersect ENT President and CEO Lisa Earnhardt Named One of Bay Area's "Most Influential Women in Business"

Menlo Park, Calif. – May 3, 2013 – Intersect ENT, Inc. is pleased to announce that President and CEO Lisa Earnhardt has been named one of the Bay Area's Most Influential Women in Business by the *San Francisco Business Times*. The annual listing, which the newspaper has published for more than a decade, recognizes outstanding women professionals who make a difference in their companies, industries and communities.

Ms. Earnhardt, a medical device executive with more than twenty years of experience in healthcare, received this recognition as a result of her impressive professional achievements and her commitment to her community. In her role as President and CEO at Intersect ENT she has raised more than \$80 million from venture capital firms to develop groundbreaking solutions for patients with chronic sinus disease. The company has launched two first-in-class medical devices, and has initiated clinical trials evaluating less invasive, more cost-effective treatment options for sinus sufferers.

"I am honored to be recognized among the many great women executives in the Bay Area," stated Ms. Earnhardt. "I am proud to have built an incredibly talented and dedicated team who are making a real difference in the lives of patients. I'd like to accept this award on behalf of the phenomenal women in the medtech industry who do amazing work and who will be accepting awards like this in the future."

"Lisa has done an outstanding job of building Intersect ENT into a successful commercial company," said Dana Mead, Kleiner Perkins Caufield & Byers. "The combination of her unique skills and ability to consistently deliver exceptional results positions Lisa to be an influential leader in Life Sciences for many years to come."

Prior to joining Intersect ENT, Ms. Earnhardt was the president of Boston Scientific's Cardiac Surgery division, now Maquet Cardiovascular, with \$200M in revenue and more than 450 employees. She was instrumental in the sale of that business in 2008 for \$750M. Previously, Ms. Earnhardt built her career at Guidant Corporation, a major cardiovascular medical device manufacturer, having joined after business school and rising to Vice President of Sales and Marketing for one of Guidant's fastest-growing businesses. She has extensive experience with global product launches and driving adoption of new technologies and began her career providing management consulting services to healthcare provider organizations at APM Inc./CSC Healthcare.

Ms. Earnhardt received a Bachelor of Science in industrial engineering from Stanford University, and holds an MBA from Northwestern's Kellogg School of Management. She serves on the boards of Intersect ENT and the Kellogg Alumni Council, where she serves as Chair. She is also a member of the Golden Gate Chapter of the Young Presidents' Organization. Ms. Earnhardt is a former Director of Kensey Nash, a leader in regenerative medicine in the fields of cardiology, orthopedics, spine and general surgery (NASDAQ: KNSY, acquired by DSM in 2012). In addition, she supports various local schools and charities, and especially enjoys volunteering in her son's kindergarten classroom.

About Intersect ENT

Intersect ENT Inc., located in Menlo Park, Calif., is an innovator in local drug delivery focused on advancing clinically proven therapy solutions that improve quality of life for patients with ear, nose and throat conditions. The company's initial products, the PROPEL and PROPEL mini dissolvable steroid-releasing implants, improve sinus surgery outcomes for patients suffering from chronic sinusitis. Chronic sinusitis is a common condition that affects one out of seven adults in the U.S. and greatly impacts quality of life. The company holds twenty issued U.S. patents and more than 75 patents and pending applications worldwide. Intersect ENT is backed by Kleiner, Perkins, Caufield, & Byers; U.S. Venture Partners; PTV Sciences; Norwest Venture Partners (NVP); and Medtronic. For more information please visit www.intersectENT.com.

###



2013 © Intersect ENT Inc. All rights reserved. INTERSECT ENT[®] and PROPEL[™] are trademarks of Intersect ENT, Inc.

Patients with Chronic Sinusitis should consult their ENT surgeon for a full discussion of risks and benefits to determine whether this product is the right choice.

Media Contact:
Nicole Osmer
650.454.0504
nicole@nicleosmer.com